DOJ Signals Increased Scrutiny on Information Sharing
February 10, 2023 Click for PDF On February 2, 2023, DOJ announced the withdrawal of
increased
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Summary Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2,